Treats edema. ANDA 208805, held by Amneal Pharms Co. Ethacrynic Acid.
As of Nov 16, 2026, ANDA 208805 (Ethacrynic Acid), held by Amneal Pharms Co, was first approved by FDA on May 8, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ethacrynic acid tablets are indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 8, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ethacrynic Acid25MG · tablet;oral | Ethacrynic Acid | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters